Filtered By:
Specialty: Drugs & Pharmacology
Procedure: Transplants

This page shows you your search results in order of date.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation
ConclusionsThe consistency of patisiran PK and PD between patients with and without LT suggests that neither LT nor concomitantly administered immunosuppressants influence hepatic uptake or RNAi activity of patisiran. The patisiran dosing regimen of 0.3 mg/kg q3w is appropriate for hATTR amyloidosis patients with or without LT.Clinical Trial Registration NoNCT03862807.
Source: Clinical Pharmacokinetics - August 28, 2023 Category: Drugs & Pharmacology Source Type: research

Asiatic acid alleviates cisplatin-induced renal fibrosis in tumor-bearing mice by improving the TFEB-mediated autophagy-lysosome pathway
Biomed Pharmacother. 2023 Jul 4;165:115122. doi: 10.1016/j.biopha.2023.115122. Online ahead of print.ABSTRACTNephrotoxicity is a major side effect of cisplatin treatment of solid tumors in the clinical setting. Long-term low-dose cisplatin administration causes renal fibrosis and inflammation. However, few specific medicines with clinical application value have been developed to reduce or treat the nephrotoxic side effects of cisplatin without affecting its tumor-killing effect. The present study analyzed the potential reno-protective effect and mechanism of asiatic acid (AA) in long-term cisplatin-treated nude mice suffer...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 6, 2023 Category: Drugs & Pharmacology Authors: Xiao-Cui Chen Li-Feng Huang Ji-Xin Tang Dan Wu Ning An Zhen-Nan Ye Hui-Yao Lan Hua-Feng Liu Chen Yang Source Type: research

Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases
Drug Discov Today. 2023 May 8:103612. doi: 10.1016/j.drudis.2023.103612. Online ahead of print.ABSTRACTDrugs of unknown mechanisms of action are no longer being developed because we have largely capitalized on our improved understanding of the immunopathogenesis of immune-mediated inflammatory diseases (IMIDs) to develop therapeutic monoclonal antibodies (mAbs) and targeted treatments. These therapies have profoundly revolutionized the care of IMIDs. However, because of the heterogeneity of IMIDs and the redundancy of the targeted molecular pathways, some patients with IMIDs might not respond to a specific targeted drug or...
Source: Drug Discovery Today - May 10, 2023 Category: Drugs & Pharmacology Authors: Renaud Felten Philippe Mertz Eden Sebbag Marc Scherlinger Laurent Arnaud Source Type: research

lncRNA OR3A4 Promotes the Proliferation and Metastasis of Ovarian Cancer Through KLF6 Pathway
Conclusion: lncRNA OR3A4 promotes the proliferation and metastasis of ovarian cancer through the KLF6 pathway.
Source: Frontiers in Pharmacology - October 27, 2021 Category: Drugs & Pharmacology Source Type: research

Alternol Sensitizes Renal Carcinoma Cells to TRAIL-Induced Apoptosis
Conclusion: Taken together, our research suggested that alternol increased TRAIL-mediated apoptosis via inhibiting antiapoptotic proteins and upregulating DR5 levels via ROS generation and the CHOP pathway.
Source: Frontiers in Pharmacology - March 25, 2021 Category: Drugs & Pharmacology Source Type: research

Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel
Publication date: December 2019Source: Biomedicine & Pharmacotherapy, Volume 120Author(s): Xiao Xu, Jingkui Xu, Chongyu Zhao, Xiuying Hou, Mengjia Li, Liwei Wang, Lixin Chen, Yehui Chen, Linyan Zhu, Haifeng YangAbstractThe enhancement of the anticancer activity by disulfiram (DSF) chelated with copper (DSF/Cu2+) has been investigated recently, while the underlying molecular mechanisms still need to be fully elucidated. Chloride channel-3 (ClC-3) is over-expressed in a variety of cancers and involves multiple tumor biological events. However, whether the over-expression of ClC-3 in tumor cells affects the sensitivity of ant...
Source: Biomedicine and Pharmacotherapy - October 12, 2019 Category: Drugs & Pharmacology Source Type: research

Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel.
Abstract The enhancement of the anticancer activity by disulfiram (DSF) chelated with copper (DSF/Cu2+) has been investigated recently, while the underlying molecular mechanisms still need to be fully elucidated. Chloride channel-3 (ClC-3) is over-expressed in a variety of cancers and involves multiple tumor biological events. However, whether the over-expression of ClC-3 in tumor cells affects the sensitivity of anti-tumor drugs remains unclear. Here, we showed that the involvement of ClC-3 chloride channel in the selective cytotoxicity of DSF/Cu2+ in the poorly-differentiated nasopharyngeal carcinoma. The EC50 o...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 9, 2019 Category: Drugs & Pharmacology Authors: Xu X, Xu J, Zhao C, Hou X, Li M, Wang L, Chen L, Chen Y, Zhu L, Yang H Tags: Biomed Pharmacother Source Type: research

Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD. Introduction Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research

Plant-Derived Alkaloids: The Promising Disease-Modifying Agents for Inflammatory Bowel Disease
Conclusion This paper summarizes the current findings regarding the anti-colitis activity of plant-derived alkaloids and shows how these alkaloids exhibit significant and beneficial effects in alleviating colonic inflammation. These natural alkaloids are not only promising agents for IBD treatment but are also components for developing new wonder drugs. However, the underlying molecular mechanisms or toxicological evaluation of most plant-derived alkaloids still require much scientific research, and their actual efficacies for IBD patients have not been verified well in field research. Thus, further clinical trials to elu...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
Abstract Transthyretin (TTR) amyloidosis, also known as transthyretin-related familial amyloidotic polyneuropathy (ATTR-FAP), is a fatal hereditary systemic amyloidosis caused by mutant forms of TTR. Although conventional treatments for ATTR-FAP, such as liver transplantation (LT) and TTR tetramer stabilizer, reportedly halt the progression of clinical manifestation, these therapies have several limitations. Oligonucleotide-based therapy, e.g. small interfering RNA (siRNA)- and antisense oligonucleotides (ASOs)-based therapy, hold enormous potential for the treatment of intractable diseases such as ATTR-FAP, by sp...
Source: Biological and Pharmaceutical Bulletin - December 8, 2018 Category: Drugs & Pharmacology Authors: Hayashi Y, Jono H Tags: Biol Pharm Bull Source Type: research

Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies. PMID: 30084326 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Marinho HS, Marcelino P, Soares H, Corvo ML Tags: Curr Pharm Des Source Type: research

Study on the function and mechanism of long non-coding RNA DMTF1v4 in the occurrence of colon cancer.
CONCLUSIONS: The expression of lncRNA DMTF1v4 is elevated in colon cancer tissues; lncRNA DMTF1v4 promotes colon cancer cell proliferation and migration, and inhibits apoptosis by downregulating the expression of p-ERK, p-JNK, and p-p38, thus affecting the progression of colon cancer. This will provide a basis for the development of new clinical treatments for colon cancer. PMID: 29949153 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 29, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

MiR-99a suppress proliferation, migration and invasion through regulating insulin-like growth factor 1 receptor in breast cancer.
CONCLUSIONS: Our findings demonstrated that miR-99a could inhibit the malignancy of breast cancer cell by directly down-regulation of IGF-1R. These results indicated that miR-99a may be an important biomarker for prognosis and anticancer therapy in breast cancer in the future. PMID: 27212167 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - May 25, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research